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SUMMARY
Defects in the repair of DNA interstrand crosslinks
(ICLs) are associatedwith the genome instability syn-
drome Fanconi anemia (FA). Here we report that cells
with mutations in RFWD3, an E3 ubiquitin ligase that
interacts with and ubiquitylates replication protein A
(RPA), show profound defects in ICL repair. An amino
acid substitution in the WD40 repeats of RFWD3
(I639K) found in a new FA subtype abolishes interac-
tion of RFWD3 with RPA, thereby preventing RFWD3
recruitment to sites of ICL-induced replication fork
stalling. Moreover, single point mutations in the
RPA32 subunit of RPA that abolish interaction with
RFWD3 also inhibit ICL repair, demonstrating that
RPA-mediated RFWD3 recruitment to stalled re-
plication forks is important for ICL repair. We also
report that unloading of RPA from sites of ICL induc-
tion is perturbed in RFWD3-deficient cells. These
data reveal important roles for RFWD3 localization
in protecting genome stability and preserving human
health.
INTRODUCTION
DNA interstrand crosslinks (ICLs) form when bifunctional agents
covalently link the two strands in the DNA double helix. Although
ICLs can be repaired in a replication-independent manner, the
dominant mode of ICL repair is thought to occur in S phase,
when replisomes collide with these lesions (Akkari et al., 2000;
Taniguchi et al., 2002; Figure S1). ICL repair is a complex process
requiring cooperation between several distinct DNA repair path-
ways (Kim and D’Andrea, 2012). The importance of efficient ICL
repair is underscored by the finding that mutations in ICL repair
are associatedwithFanconi anemia (FA), a rare recessive disorder
typified by developmental abnormalities, bone marrow failure,
and increased incidence of cancers (Auerbach, 2009; Kim and
D’Andrea, 2012). Twenty-one FA genes have been reported to
date, and studying the products of these genes (the FANC pro-
teins) has provided important insights into ICL repair.
The central components of the FA pathway, FANCD2 and its
paralog FANCI, together form the ‘‘ID’’ complex (Garcia-Higuera
et al., 2001; Smogorzewska et al., 2007). These proteins are
mono-ubiquitylated at Lys561 and Lys523, respectively, both
in S phase and in response to ICLs (Garcia-Higuera et al.,
2001; Taniguchi et al., 2002). These reactions are catalyzed by
the E3 ubiquitin ligase FANCL, a subunit of the FA core complex,
in concert with the E2-conjugating enzyme FANCT and the FA-
associated proteins FAAP100 and FAAP24 (Ciccia et al., 2007;
Collis et al., 2008; Ling et al., 2007). Mono-ubiquitylation of
FANCD2 is necessary for ICL repair (Kim and D’Andrea, 2012;
Knipscheer et al., 2009); however, the underlying molecular
mechanisms remain unclear. The FAN1 nuclease is recruited to
stalled replisomes by ubiquitin-FANCD2, but this interaction is
dispensable for ICL repair and is instead required for the protec-
tion of stalled forks in a general sense (Lachaud et al., 2016a,
2016b). FANCD2 ubiquitylation is known to promote lesion ‘‘un-
hooking,’’ involving nucleolytic incisions on either side of the ICL
(Figure S1) that appear to require the XPF-ERCC1 nuclease
(Knipscheer et al., 2009). After unhooking, the resulting gap is
thought to be filled in by translesion synthesis. The unhooked
lesion can subsequently be removed by excision repair, and
the double-strand breaks (DSBs) generated by the unhooking
step are ultimately repaired by homologous recombination
(HR) (Figure S1).
Recently, it was reported that the RING finger-type E3 ubi-
quitin ligase RFWD3 affects HR at stalled replication forks
(Elia et al., 2015). RFWD3 was already known to interact with
the RPA32 subunit of the replication protein A (RPA) complex,
a heterotrimeric complex essential for multiple aspects of DNA
replication, repair, and recombination. Translocation of RFWD3
to sites of replication fork stalling appears to require interaction
with RPA (Gong and Chen, 2011; Liu et al., 2011). More recently,
it was shown that RFWD3 promotes RPA ubiquitylation in vivo
in response to agents that cause fork stalling, such as
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hydroxyurea (HU), which depletes deoxyribonucleotide triphos-
phates (dNTPs). All three RPA subunits—RPA70, RPA32, and
RPA14—appear to be ubiquitylated by RFWD3, but the func-
tional effect of RFWD3-mediated ubiquitylation on RPA is not
yet clear. Cells depleted of RFWD3 show defects in restart of
forks stalled after exposure of cells to HU and also show defects
in HR at a protein-DNA roadblock that causes fork stalling (Elia
et al., 2015). However, it remains to be seen whether RPA ubiq-
uitylation is relevant to the fork-protective functions of RFWD3
or, indeed, whether the E3 activity of RFWD3 is required. Atten-
uation of the RPA-RFWD3 interaction through deletion of a small
region in the C terminus of RPA32 not only abolishes RPA ubiq-
uitylation but also reduces the efficiency of HR at a protein-DNA
roadblock. However, mutating the ubiquitylated residues K37
and K38 in RPA32 inhibited RPA32 ubiquitylation without
affecting HR (Elia et al., 2015). Therefore, it is not yet clear
whether RPA ubiquitylation is relevant for DNA repair or whether,
instead, RPA simply recruits RFWD3 to stalled forks, where it
ubiquitylates other substrates to control genome stability.
Here we show that interfering with RFWD3 function causes
key hallmarks of defective ICL repair. An RFWD3mutation found
in a new FA subtype inhibits ICL repair by abolishing the interac-
tion of RFWD3 with RPA. Moreover, RFWD3 controls RPA dy-
namics, and point mutations in RPA that abolish its interaction
with RFWD3 attenuate ICL repair. These data reveal that the
interaction of RFWD3 with RPA is vital for ICL repair and for pre-
serving human health.
RESULTS
Generating RFWD3-Deficient Human Cells
Recently, mutations in the gene encoding the E3 ubiquitin ligase
RFWD3 were found in a new FA subtype, suggesting a role for
RFWD3 in ICL repair (D.S., unpublished data). To test this possi-
bility, we used CRISPR/Cas9-mediated genome editing to
disrupt the RFWD3 gene in HeLa cells. Although we succeeded
in knocking out other genes, including ERCC1 (Figure S2A), we
failed to obtain clones that completely lacked RFWD3 protein
even after using a range of guide RNAs (gRNAs). Similar results
were obtained in U2OS cells (data not shown), suggesting that
RFWD3 might be essential for cell viability. However, analysis
of genomic DNA from a range of HeLa cell clones obtained using
a gRNA targeting exon 4 revealed a high frequency of homozy-
gous alterations at the RFWD3 locus (data not shown). We
reasoned that these clones might harbor hypomorphic RFWD3
mutations that could affect DNA repair. We therefore screened
clones for the ability to survive exposure to a single dose of the
ICL-inducing drug mitomycin-C (MMC) using the low-sensitivity,
high-throughput MTS assay. As shown in Figure S2B, several
clones obtained after targeting RFWD3 exon 4 showed
reduced ability to survive MMC exposure compared with con-
trol HeLa cells. RT-PCR analysis of mRNA isolated from clone
7, for example, revealed compound heterozygosity at the
RFWD3 locus. One allele harbors a deletion of 13 bases within
exon 4 and an insertion of four random bases within the gRNA-
binding sequence, which together resulted in replacement of
amino acids 254–258 (IDGGK) in the linker domain with two
random amino acids (NW), after which the RFWD3 sequence
is normal right to the end of the reading frame (Figures S2C–
S2E). The second allele harbors a deletion in exon 4, which
changes the frame and introduces a premature stop codon,
thereby truncating the protein from Glu240, with
the introduction of six extra amino acids (Figures S2F–S2H).
Western blotting of cell extracts of clone 7 revealed an
RFWD3 species of similar molecular weight as wild-type (WT)
RFWD3 (Figure S2A), which we presume to be the product of
the first allele mentioned above (Figures S2C–S2E). We refer
to the RFWD3-hypomorphic HeLa cells as RFWD3D/D cells
hereafter.
RFWD3D/DCells ShowHallmarks of Defective ICL Repair
Tomore accurately measure the sensitivity of RFWD3D/D cells to
DNA crosslinking agents, we decided to carry out clonogenic
survival assays. As shown in Figure 1A, RFWD3D/D cells are pro-
foundly hypersensitive to agents that induce ICLs, such asMMC
and cisplatin. The extreme sensitivity ofRFWD3D/D cells to these
crosslinking agents is comparable with HeLa cells lacking
ERCC1, a gene that encodes a subunit of the FA protein com-
plex ERCC1-XPF (Bogliolo et al., 2013; Figure S3A). In contrast,
RFWD3D/D cells show no hypersensitivity to HU, which stalls
replication forks by depleting dNTPs, and are only weakly sen-
sitive to ionizing radiation (IR), which induces single- and dou-
ble-strand breaks (Figure 1A). The narrow spectrum of genotox-
ins (ICL-inducing agents) to which RFWD3D/D cells show
sensitivity argues strongly that ICL repair is a major function of
RFWD3. We therefore tested RFWD3D/D cells for other hall-
marks of defective ICL repair. Exposure to a low dose of MMC
caused a high proportion of RFWD3D/D cells, but not control
cells, to accumulate in G2 phase. This pronounced G2 arrest is
a hallmark of FA cells, and, indeed, the strength of G2 arrest
seen in RFWD3D/D cells is similar to that in ERCC1/ cells (Fig-
ure 1B). We also noticed that RFWD3D/D cells showed an
increased incidence of spontaneous chromosome abnormal-
ities, defined by chromatid breaks and radial chromosome
structures (Figure 1C). The frequency of abnormalities increased
after exposure to MMC to a level higher than observed in control
cells (Figure 1C). Again, the increased frequency of chromo-
some abnormalities in RFWD3D/D cells was comparable with
ERCC1/ cells.
We also carried out a crude epistasis-type experiment by
depleting FANCD2 from RFWD3D/D cells. Cells defective in
both RFWD3 and FANCD2 were not more sensitive to MMC
than RFWD3D/D cells (Figures S3B and S3C), which strongly
suggests that RFWD3 is part of the FA network, consistent
with the identification of RFWD3 as a bona fide FANC protein.
Furthermore, the ubiquitylation of FANCD2 induced by exposure
of cells to MMC occurs normally in RFWD3D/D cells (Figure S3D).
Taken together, these data reveal that RFWD3 is important for
the repair of ICLs and appears to act downstream of FANCD2
in the FA pathway.
The FA-Derived I639K Mutation Abolishes RFWD3
Interaction with RPA
As mentioned above, a new FA subtype has recently been iden-
tified that is associated with mutations in RFWD3, termed here-
after FA-RFWD3 (D.S., unpublished data). So far, only one
Molecular Cell 66, 610–621, June 1, 2017 611
patient has been identified, showing compound heterozygosity
at the RFWD3 locus (Figure S4). In one allele, a frameshift results
in the introduction of a premature stop codon, which should trun-
cate the protein product at amino acid Leu69. In contrast, the
second allele harbors a single point mutation, I639K, located
within theWD40 domain at the C terminus of RFWD3 (Figure S4).
It is likely that the RFWD3-I639K point mutant is the only form of
RFWD3 expressed in FA-RFWD3 cells. In light of this, we wanted
to investigate the effect of this mutation on the ICL repair func-
tions of RFWD3. We reasoned that the I639K mutation may
disrupt the interaction of RFWD3 with RPA, and we set out to
test this possibility. RPA was detected in anti-GFP immunopre-
cipitates from cells stably expressing GFP-tagged RFWD3 (Fig-
ure 2A), although the signal was weak and varied widely between
experiments. We found that introducing a C315A mutation in the
active site of RFWD3, which renders the recombinant protein
inactive in vitro (Figure S5), stabilized RFWD3, resulting in
increased expression, and made the interaction with RPA easier
to detect (Figure 2A). Exposure of cells to MMC resulted in a
dose-dependent increase in the amount of RPA in RFWD3 pre-
cipitates (Figure 2B); we observed a similar increase in several in-
dependent experiments, but the fold increase varied between
experiments for reasons that are unclear (data not shown).
Remarkably, introducing the FA-associated I639K mutation
completely abolished the co-immunoprecipitation of RPA with
GFP-RFWD3 C315A without affecting RFWD3 C315A expres-
sion levels (Figure 2B).
Ile639 is located within the WD40 domain of RFWD3, toward
the C terminus (Figure S4). WD40 domains are known to be
involved in mediating protein-protein interactions and are
generally composed of six to eight structurally conserved
WD40 repeats. Each of these repeats contains four anti-parallel
b strands that fold into a conserved b-propeller structure,
exposing three types of surface—top, bottom, and side (Stirni-
mann et al., 2010). Certain ‘‘hotspot’’ residues on these surfaces
engage in protein-protein interactions that play important roles
in various cellular functions (Wu et al., 2003). Recently, a data-
base of WD40 proteins was reported (WDSPdb) that uses an al-
gorithm to identify WD40 repeats in query proteins, predict sec-
ondary structure, and pinpoint surface hotspot residues (Wang
et al., 2015b). This algorithm revealed six WD40 repeats in
RFWD3 and predicted six top-face hotspots likely to engage
in protein-protein interactions. Interestingly, this list included
I639, located in the fourth WD40 repeat (Figure 2C). We there-
fore decided to test whether, like I639, mutation of the other pre-
dicted hotspots also affected the interaction of RFWD3 with
RPA. As shown in Figure 2D, mutation of W543, but not Q499
or L518, to alanine completely abolished the interaction of
GFP-tagged RFWD3 with RPA. These data show that the FA-
associated I639K mutation prevents the binding of RFWD3 to
RPA and that the surface-exposed residue W543 is also critical
for this interaction.
The I639K Mutation Abolishes RFWD3 Recruitment
to DNA Damage Sites
Because interaction with RPA has been implicated in the
recruitment of RFWD3 to sites of HU-induced fork stalling
(Gong and Chen, 2011; Liu et al., 2011), we reasoned that the
FA-associated I639K mutation might have an effect on
RFWD3 localization to ICLs. To investigate this possibility, we
utilized ultraviolet (UV) laser-activated psoralen conjugates to
generate ICLs along a track in the nucleus and then visualized
recruitment of GFP-tagged RFWD3 to these tracks by indirect
immunofluorescence. As shown in Figure 3A, RFWD3 with a
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Figure 1. RFWD3-Deficient Cells Show Hallmarks of Defective ICL
Repair
(A) Clonogenic survival analysis of control and RFWD3D/D HeLa cells exposed
to the indicated genotoxins. For each cell type, the viability of untreated cells is
defined as 100%.Data are represented asmean ± SEM; n = 3. Control cells are
parental cells that were taken through genome editing protocols but areWT for
RFWD3. Circles, control; squares, RFWD3D/D.
(B) Cells were left untreated (mock) or treated with MMC for 24 hr before
ethanol fixation, propidium iodide staining, and fluorescence-activated cell
sorting (FACS) analysis. The proportion of cells in G2 phase is indicated in
each case.
(C) Metaphase spreads were prepared from cells of the indicated genotypes
that were left untreated or treated with MMC for 24 hr. The number of chro-
mosome breaks and radial chromosomes per metaphase spread was quan-
tified. Data are represented as mean ± SEM.
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GFP tag at the N terminus, but not GFP alone, translocates to
tracks of laser micro-irradiation and co-localizes with the phos-
phorylated form of histone variant H2AX (g-H2AX). The intensity
of the stripes formed by the C315A catalytically inactive
RFWD3 mutant was noticeably higher than that of WT
RFWD3 (Figure 3A). Live imaging analysis revealed that GFP-
RFWD3 is recruited to ICLs within 5 min of ICL induction, reach-
ing maximum intensity at around 20 min (Figure 3B). By 80 min,
the GFP-RFWD3 stripe had almost disappeared. The C315A
A
B
C
D
Figure 2. The FA-Derived RFWD3 I639K
Mutant Cannot Interact with RPA
(A) U2OS cells stably expressing GFP-RFWD3
(WT or a catalytically inactive C315A mutant) or
GFP only were exposed to HU (2 mM) or MMC
(50 ng/mL) for 16 hr and then lysed. Anti-GFP
immunoprecipitates were probed with the indi-
cated antibodies. In the case of IR, cells were
exposed to 10 Gy and left to recover for 1 hr
before lysis.
(B) U2OS cells stably expressing GFP-RFWD3
(C315A or C315A I639K) or GFP only were
exposed to the indicated concentrations of MMC
for 16 hr and then lysed and analyzed as in (A).
(C) The human RFWD3 amino acid sequence was
entered into the WD40 repeat prediction algo-
rithm at the WDSPdb database. The table pre-
dicts six WD40 repeats (WD 1–6). For each
repeat, the sequence of the four anti-parallel b
strands typical of WD40 repeats is given, as well
as the sequence of loops connecting these b
strands. In red are shown predicted surface hot-
spots that, in other WD40 domain proteins,
mediate key protein-protein interactions.
(D) Same as (B), except that U2OS cells ex-
pressing GFP-RFWD3 C315A or GFP-RFWD3
C315A bearing mutations in the predicted WD40
hotspots described in (C) were treated with a
single dose of MMC for 16 hr before analysis.
mutant was recruited with comparable
kinetics, although, again, the stripe in-
tensity was higher than that of the WT.
Intriguingly, however, the C315A mutant
persisted at sites of ICL induction and
appeared to continue to increase in in-
tensity even at the 80-min time point
(Figure 3B). These data suggest that
RFWD3 activity is necessary for its
own removal from DNA damage sites
but not for its recruitment. Strikingly,
introducing the I639K mutation pre-
vented localization of GFP-RFWD3
C315A to tracks of ICL induction (Fig-
ure 3A). To confirm these results, we
also examined RFWD3 localization to
sub-nuclear foci induced by exposure
to MMC. As shown in Figure S6, GFP-
RFWD3 C315A forms subnuclear foci
in response to MMC treatment, and
these foci co-localize with RPA. How-
ever, the I639K mutation completely abolishes formation of
MMC-induced RFWD3 foci (Figures 3C and 3D).
We next tested the effect of mutating the WD40 surface hot-
spot residues described above (Figure 2C) on RFWD3 localiza-
tion. As shown in Figure 3E, mutating Q499 or L518, which did
not affect interaction of RFWD3 with RPA, had little effect on
recruitment of GFP-RFWD3 to sites of ICL induction. However,
mutating W543, which prevents interaction with RPA, abolishes
recruitment of GFP-RFWD3 (Figure 3E), similar to the I639K
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mutation. Therefore, only WD40 mutations that abolish RPA
binding prevent recruitment of RFWD3 to sites of ICL induction.
The I639K Mutation Abolishes ATR-Catalyzed RFWD3
Phosphorylation
It has been reported previously that RFWD3 is phosphorylated
by the ataxia telangiectasia mutated (ATM) and ataxia telangiec-
tasia mutated-related (ATR) kinases following ionizing radiation
(Fu et al., 2010; Matsuoka et al., 2007; Mu et al., 2007). An anti-
body against BRCA1 phospho-S1457 was reported to recognize
phospho-RFWD3 after IR (Fu et al., 2010), and we found that
GFP-RFWD3, but not GFP, cross-reacts with these antibodies
after exposure of cells to MMC (Figure 4A). The residues flanking
S46 and S63 of RFWD3 resemble those around BRCA1 S1457
(Fu et al., 2010), and, accordingly, mutating both of these resi-
dues together completely abolished the cross-reactivity of
GFP-RFWD3 with the BRCA1 phospho-S1457 antibody after
MMC treatment (Figure 4A). Phosphatase treatment of GFP-
RFWD3 immunoprecipitates also abolished cross-reactivity
with BRCA1 phospho-S1457 antibodies (Figure 4B). Further-
more, pre-incubation of cells with the specific ATR inhibitor
ETP-46464 (Toledo et al., 2011), but not the ATM inhibitor KU-
55933 (Hickson et al., 2004), blocked RFWD3 phosphorylation
after MMC, suggesting that this phosphorylation is predomi-
nantly mediated by the ATR kinase (Figure 4C). As shown in Fig-
ures 4D and 4E, MMC-induced RFWD3 phosphorylation is both
dose and time dependent. RFWD3 phosphorylation is not
observed until around 6 hr after exposure of cells to MMC,
with the phospho-specific signal increasing up to 24 hr. This
lag in RFWD3 phosphorylation suggests that entry to S-phase
is required, which is consistent with the requirement for ATR.
As shown in Figure 4F, introducing the FA-associated I639K
mutation completely abolished phosphorylation of GFP-
RFWD3 C315A.
Altered RPADynamics at ICLs inRFWD3-Defective Cells
We next set out to test the effect of RFWD3 on RPA dynamics at
sites of ICL induction. To this end, the proportion of cells with
more than five RPA32 foci after exposure of cells to a transient
pulse of MMC was quantitated. As shown in Figure 5A, the pro-
portion of control cells with more than five RPA32 foci rose to
reach a maximum of around 40% after 12–24 hr, declining to
near-basal levels by 48 hr. The proportion of RFWD3D/D
cells with more than five RPA32 foci rose to almost 80% at the
24-hr time point and started to decline thereafter (Figure 5A).
However, at 48 hr, when hardly any control cells had RPA foci,
around 45% of RFWD3D/D cells still had more than five foci. A
similar difference between control and RFWD3D/D cells was
observed when the number of RPA foci per cell was quantitated
(Figure S7A).
During HR, RPA should be displaced from single-stranded
DNA (ssDNA) to allow formation of the RAD51 nucleofilament,
and we wondered whether the persistence of RPA at sites of
ICL induction in RFWD3-defective cells might prevent the
loading of RAD51. We investigated this possibility by analyzing
the appearance and disappearance of RAD51 foci from sites of
ICL induction in the same manner as described above for
RPA32. In control cells, RAD51 loaded onto sites of ICL induc-
tion, as assessed by quantitating the proportion of cells with
more than five foci, reaching a maximum and plateauing by
24 hr (Figure 5B). By 72 hr, the foci had declined substantially.
Intriguingly, RAD51 appeared to load normally in RFWD3D/D
cells, and, if anything, a slightly higher proportion of RFWD3D/D
cells had more than five RAD51 foci compared with control cells.
In both cell lines, RAD51 foci had declined in number by 72 hr,
although the proportion of RFWD3D/D cells with RAD51 foci
was still notably higher than WT. (Figures 5B and S7B). It is inter-
esting to note that at the 48 hr post-recovery time point,
RFWD3D/D cells had close to normal levels of RAD51 foci despite
failure of RPA to dissociate.
We next employed high-resolution microscopy to investigate
the co-localization of RPA and RAD51 at times during recovery
when RPA foci were found to persist in RFWD3D/D cells.
Twenty-four hours after recovery from a pulse of MMC, around
20% of RAD51 foci in both RFWD3-deficient and control cells
also contained RPA (Figure 5C, top). Broadly speaking, two
notable patterns of RAD51 and RPA localization were evident.
The first pattern involved RAD51 and RPA occupying opposite
ends of the same subnuclear focus, with co-localization (defined
by signal overlap) restricted to a central zone. The second
pattern involved RPA staining along the whole focus, with
RAD51 co-localization occurring in a central zone (Figure 5C,
bottom). At the 24-hr recovery time point, RFWD3D/D cells
were indistinguishable from control cells in the distribution of
the two broad patterns of localization of RPA and RAD51. By
the 48-hr recovery time point, almost all RPA foci had disap-
peared from control cells, and, consequently, the RAD51 foci
did not contain RPA (Figure 5C, top). However, in RFWD3D/D
cells where RPA foci persisted, around 30% of RAD51 foci still
contained RPA (Figure 5C). The patterns of RAD51 and RPA
localization under these conditions were indistinguishable from
control cells at the earlier time point (Figure 5C, bottom).
To validate these results, we also applied in situ proximity liga-
tion assay (PLA) technology. In this experiment, the RAD51 and
RPA primary antibodies are conjugated with two different oligo-
nucleotides. When in close proximity, ligation of the oligonucle-
otide moieties becomes possible, creating a DNA sequence
that can be PCR-amplified. In the presence of fluorescent
dNTPs, a fluorescent signal is generated. As shown in Figures
5D and S7C, a small number of distinct foci could be seen in
both control and RFWD3-deficient cells after 24 hr of recovery
from an MMC pulse. The number of foci visible in control cells
significantly decreased after 48 hr of recovery; however, the
number of PLA foci in RFWD3-deficient cells remained notably
higher.
Taken together, these data show that RPA persists in RFWD3-
defective cells, resulting in the presence of RPA in a subset of
RAD51 foci at time points where RPA foci have disappeared
from control cells. One possible consequence of the presence of
RPA in RAD51 foci is inhibition of strand invasion and HR.
In support of this idea, we observe that RFWD3D/D cells are
hypersensitive to the PARP inhibitor olaparib (Figure 5E), which
is a hallmark of defective HR (Lord and Ashworth, 2016). This
observation is consistent with the previous demonstration of a
major defect in HR at a protein-DNA roadblock when cells are
depleted of RFWD3 (Elia et al., 2015).
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RPA32 Mutations that Abolish Interaction with RFWD3
Attenuate ICL Repair
Given that RFWD3 affects RPA dynamics at sites of ICL induc-
tion and that the FA-associated I639K mutation in RFWD3
abolishes interaction with RPA, we wished to further investi-
gate whether the RPA-RFWD3 interaction is relevant for ICL
repair. To this end, we sought to test the effect of mutations
in RPA that abolish interaction with RFWD3. It was reported
previously that deleting amino acids 243–262 of RPA32 abol-
ishes both the interaction with RFWD3 and RPA ubiquitylation
(Elia et al., 2015; Gong and Chen, 2011); however, we sought
to make more subtle changes that would disrupt the interac-
tion with RFWD3. As shown in Figure 6A, we identified a num-
ber of conserved residues in this region of RPA32, and we
tested the effect of mutating four of these residues on the
interaction with RFWD3. We found that, although mutating
residue G253 to alanine had little effect on the ability of
FLAG-tagged RPA32 to interact with endogenous RFWD3,
mutating F248, E252, or H254 abolished the interaction of
the two proteins (Figure 6B). Importantly, the F248, E252,
and H254 mutations did not affect the interaction of RPA32
with RPA70 (Figure 6B).
We next tested the effect of replacing endogenous RPA32with
the mutants that abolish interaction with RFWD3 on ICL repair.
To this end, U2OS cells stably expressing FLAG-tagged
RPA32 (WT or mutants) were transfected with a small interfering
RNA (siRNA) targeting the 30 UTR of the RPA32 gene (Fig-
ure S7D). The RPA32 siRNA only gave partial depletion of
RPA32, which was expected given that complete knockdown
of RPA32 is incompatible with cell viability. Strikingly, cells in
which RPA32 was replaced by the F248A, E252A, or H254A mu-
tants, which cannot interact with RFWD3, were hypersensitive to
MMC, whereas the G253A mutant that can interact with RFWD3
did not render cells any more sensitive to MMC than the WT
RPA32 control (Figure 6C). Another hallmark of defective ICL
repair is the accumulation of cells in G2 phase after MMC expo-
sure. As shown in Figure 6D, control U2OS cells depleted of
RPA32 showed a pronounced accumulation in G2 phase even
without MMC treatment, and this is increased further in response
to low doses of MMC. Expression of FLAG-RPA32 (WT) reversed
the G2 accumulation caused by RPA32 depletion (both with and
without exposure of cells to MMC). Interestingly, cells in which
endogenous RPA32 was replaced by the F248A, E252A, or
H254A mutants, which cannot interact with RFWD3, showed
pronounced accumulation in G2 only after MMC exposure, indic-
ative of defective ICL repair (Figure 6D). Furthermore, replacing
endogenous RPA32with the G253Amutant, which interacts nor-
mally with RFWD3 (Figure 6B), did not cause accumulation of
cells in G2 after MMC treatment (Figure 6D). These data demon-
strate that the interaction of RFWD3 with RPA is required for the
optimal repair of ICLs.
DISCUSSION
In this study, we present evidence that RFWD3 plays an impor-
tant role in the repair of ICLs. Genome-edited, RFWD3-hypo-
morphic (RFWD3D/D) cells show all of the classic hallmarks of
defective ICL repair—hypersensitivity to MMC, pronounced
G2 arrest, and chromosome breakage after MMC exposure
(Figure 1). Consistent with this, RFWD3 was one of many fac-
tors identified recently in a screen for proteins recruited to
chromatin during ICL repair in cell-free Xenopus extracts
(R€aschle et al., 2015). Intriguingly, we were unable to isolate
RFWD3 knockout clones that were completely devoid of
RFWD3 protein despite using a range of RFWD3-specific
gRNAs in multiple cell lines under conditions used to knock
out a number of other genes. This suggests that RFWD3 may
be an essential gene, in agreement with the recent identification
of RFWD3 in genome-wide screens for essential genes in
KBM7 and HAP1 cells (Wang et al., 2015a). It is unlikely that
the essential role of RFWD3 is ICL repair, however, because
most FA gene knockouts are viable. On the other hand, several
genes controlling HR are essential, including BRCA1, BRCA2,
and RAD51. Like RFWD3, these genes mediate HR not only
during ICL repair but also in response to other DNA lesions
and other modes of fork stalling (Deans and West, 2011).
Therefore, it is tempting to speculate that the essential function
of RFWD3 reflects a critical role in HR at stalled forks. However,
the FA-associated I639K mutation completely abolishes inter-
action with RPA, and yet the patient cells are viable. So if pro-
moting HR is the essential function of RFWD3, then substrates
other than RPA must be involved. Further work involving condi-
tional RFWD3 inactivation and the identification of the full
gamut of RFWD3 substrates will be necessary to answer these
questions.
We found that the interaction of RFWD3 with RPA appears to
be critically important not only for recruitment of RFWD3 to sites
of ICL induction but also for ICL repair. We were able to
show that replacing endogenous RPA32 with mutants that
inhibit the interaction with RFWD3 causes defective ICL repair,
whereas a nearby mutation (G253A) that does not affect
RFWD3 interaction has no effect on ICL repair (Figure 6). Further-
more, mutating predicted surface hotspots in the RFWD3 WD40
repeats that abolish interaction with RPA also abolishes recruit-
ment to ICLs, whereas WD40 domain mutations that do not
affect RPA interaction have no effect on RFWD3 recruitment
Figure 3. The RFWD3 I639K Mutant Is Not Recruited to DNA Damage Sites
(A) U2OS cells stably expressingGFP, GFP-RFWD3,GFP-RFWD3C315A, or GFP-RFWD3C315A I639Kwere incubatedwith trimethyl-psoralen and subjected to
sub-nuclear micro-irradiation using a 355-nm UV laser. Cells were fixed and subjected to indirect immunofluorescence analysis with antibodies against GFP or
g-H2AX.
(B) Time-lapse live imaging of U2OS cells stably expressing GFP-RFWD3 (WT or C315A) incubated with trimethyl-psoralen and subjected to sub-nuclear micro-
irradiation using a 355-nm UV laser. The time after micro-irradiation is indicated.
(C) U2OS cells stably expressing GFP-RFWD3C315A or GFP-RFWD3C315A I639Kwere left untreated (mock) or exposed toMMC for 16 hr. Cells were fixed and
subjected to indirect immunofluorescence analysis with antibodies against GFP or g-H2AX.
(D) Quantitation of the proportion of cells in (C) with more than five RFWD3 foci.
(E) GFP-RFWD3 C315A or GFP-RFWD3 C315A bearing the WD40 repeat mutations indicated were analyzed as in (A).
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(Figures 2 and 3). Importantly, the FA-associated I639Kmutation
completely blocked both RPA binding and RFWD3 recruitment
to ICLs induced by psoralen/UV orMMC. Therefore, loss of inter-
action of RFWD3with RPA at stalled replisomes is themost likely
explanation for the ICL repair defect seen in RFWD3-deficient
cells and is likely to explain, at least partly, why the I639K muta-
tion causes FA.
We consistently observed that the interaction of RFWD3 with
RPA is stimulated by exposure of cells to ICL-inducing drugs.
This makes sense from the point of view that RFWD3 is recruited
A
B
D
E
F
C
Figure 4. Defective Phosphorylation of
RFWD3 I639K
(A) U2OS cells stably expressing GFP only, GFP-
RFWD3 WT, or GFP-RFWD3 bearing the S46A or
S63A mutations singly and in combination were
exposed to MMC for 16 hr. Anti-GFP precipitates
were probed with the antibodies indicated.
(B) GFP-RFWD3 was immunoprecipitated from
extracts of U2OS cells exposed or not to MMC
for 16 hr. Precipitates were incubated or not with
l-phosphatase in the presence or absence of
EDTA before western blotting with the indicated
antibodies.
(C) U2OS cells stably expressing GFP-RFWD3
were preincubated with or without the ATR inhib-
itor ETP-46464 (5 mM) or the ATM inhibitor KU-
55933 (5 mM) and then analyzed as in (A).
(D and E) U2OS cells stably expressing GFP-
RFWD3 were exposed to MMC at the indicated
doses for 16 hr (D) or withMMC (100 ng/mL) for the
indicated times (E) and analyzed as in (A).
(F) U2OS FRT cells stably expressing GFP-
RFWD3 (C315A or C315A + I639K) were treated
with the indicated doses of MMC for 16 hr. Cells
were lysed, and anti-GFP precipitates were pro-
bed with the indicated antibodies.
to replication forks only when they stall.
However, the mechanism whereby ICL-
inducing drugs stimulate the RFWD3-
RPA interaction is not clear. RFWD3 is
known to be phosphorylated in response
to fork stalling, but we found that the
ATR inhibitor ETP-46464, which prevents
RFWD3 phosphorylation (Figure 4), has
no effect on the inducible interaction of
RFWD3 with RPA and does not affect
RFWD3 recruitment to DNA damage
sites (data not shown). Therefore, more
work is required to determine how ICL-
inducing agents promote the interaction
of RFWD3 with RPA.
It is not yet clear whether ubiquitylation
of RPA is required for the fork protec-
tion and/or ICL repair roles of RFWD3.
An RPA32 mutant (K37R K38R) that
shows a major reduction in ubiquitylation
induced by HU was shown to be profi-
cient for HR and resolution of gH2AX
foci, arguing that RPA32 might not be a substrate of RFWD3
relevant for ICL repair (Elia et al., 2015). Although it is possible
that it is the ubiquitylation of the other subunits of RPA that is
important, currently there is no supporting evidence for this hy-
pothesis. Indeed, it could be argued that RPA simply recruits
RFWD3 to stalled forks, where it then ubiquitylates other sub-
strates to promote HR and genome stability. However, one
argument in favor of RPA ubiquitylation promoting ICL repair
comes from our observation that RPA dynamics at sites of
ICL-induced fork stalling are perturbed in RFWD3D/D cells
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(Figure 5). It is perhaps difficult to explain this defect without
invoking RFWD3 catalytic activity, and, on this basis, we spec-
ulate that RPA ubiquitylation facilitates the unloading of RPA
from resected DNA ends during HR. It is not yet clear how
RFWD3-catalyzed ubiquitylation might facilitate RPA dissocia-
tion. It may be that RFWD3 increases the turnover of RPA to
promote dissociation from broken replication forks, and, in this
light, it is worth noting that inactivating RFWD3 catalytic activity
boosts the levels of this protein, suggesting that it might control
its own turnover (Figures 2A and S5). It is also possible that RPA
A
B
C
D E
RFWD3
RFWD3
RFWD3RFWD3
RFWD3 RFWD3
Figure 5. Altered RPA Dynamics at ICLs in
RFWD3-Deficient Cells
(A and B) Control or RFWD3D/D HeLa cells were
exposed to MMC for 2 hr and then washed free of
drug and allowed to recover for the indicated
times. Cells were pre-extracted, fixed, and sub-
jected to immunofluorescence analysis to detect
the proportion of cells with more than five RPA32
foci (A) or RAD51 foci (B). Control cells were
parental cells that were taken through genome
editing protocols but were WT for RFWD3. Data
are represented as mean ± SEM, n = 3.
(C) Control orRFWD3D/DHeLa cells were exposed
to MMC for 2 hr and then washed free of drug and
allowed to recover for the indicated times. Cells
were then treated, fixed, and subjected to immu-
nofluorescence as in (A) (top). Individual nuclei
were then imaged at high resolution (633 oil im-
mersion lens, pinhole 0.5 Airy unit [AU]) to
examine the structure of RPA32 and RAD51 foci
(bottom).
(D) Control orRFWD3D/DHeLa cells were exposed
to MMC for 2 hr and then washed free of drug
and allowed to recover for the indicated times.
Cells were then incubated with RPA32 and
RAD51 primary antibodies conjugated to different
oligonucleotides. Ligation and amplification with
fluorescent dNTPs were then carried out, and the
number of fluorescent foci per nucleus was
quantified for each sample. Data are represented
as mean ± SEM; n = 3.
(E) Clonogenic survival analysis of control and
RFWD3D/D HeLa cells subjected to chronic
treatment with the indicated doses of olaparib.
For each cell type, the viability of untreated cells
is defined as 100%. Data are represented as
mean ± SEM; n = 3.
ubiquitylation enhances its interaction
with one or more proteins that facilitate
its extraction from ssDNA, such as the
p97 segregase. Testing these possibil-
ities will be an interesting line of future
investigation.
Even if RPA ubiquitylation by RFWD3
is required for RPA unloading from ICL-
induced foci, it does not necessarily
follow that the persistence of RPA
seen in RFWD3D/D cells is sufficient
to derail the HR process, especially
because RAD51 appears to load nor-
mally in these cells. In other words,
altered RPA dynamics may not be the cause of the HR defects
noted in RFWD3-deficient cells (Figure 5E; Elia et al., 2015).
However, it is possible that the presence of RPA in RAD51
foci impedes the formation of the RAD51 nucleofilament,
thereby inhibiting strand invasion and HR. It therefore seems
reasonable to speculate that a failure in HR—caused perhaps
by loss of RPA ubiquitylation—is responsible for both the
defect in ICL repair and the FA disease phenotype seen in
the context of RFWD3 mutations. This is particularly relevant
given that mutations in key HR factors such as BRCA1 and
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BRCA2 have also been found to cause major defects in ICL
repair as well as FA (Deans and West, 2011).
Over the past decade it has become clear that the replace-
ment of RPA with RAD51 on resected forks is a complex trans-
action requiring a range of proteins, including the mediator pro-
teins RAD51B–RAD51D, XRCC2, and XRCC3 (Krejci et al.,
2012). The BRCA2 tumor suppressor is also involved in this
process, promoting the assembly of a RAD51 nucleofilament
on ssDNA both in the context of ICL repair as well as the repair
of DSBs in general (Krejci et al., 2012; Liu et al., 2010). Addi-
tionally, other proteins, such as the MMS22L-TONSL complex,
have been implicated in replacing RPA with RAD51, at least in
the context of replication-associated DSBs (Duro et al., 2010;
O’Donnell et al., 2010). Determining exactly how the removal
of RPA is coordinated with RAD51 loading and nucleofilament
formation will be a major challenge for the future, as will deter-
mining the precise role of RFWD3 in this surprisingly complex
process.
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KU59933 (ATM inhibitor) Hickson et al., 2004 N/A
Critical Commercial Assays
CellTiter 96 cell proliferation assay kit (MTS assay) G5421
Duolink Probemaker Plus kit DUO92009
Duolink Probemaker Minus kit DUO92010
Duolink detection kit green DUO92014
Deposited Data
Raw imaging data this paper Mendeley data:
http://dx.doi.org/10.17632/brzwywcrbj.1
Experimental Models: Cell Lines
U2OS FRT in house N/A
HeLa FRT FLAG-CAS9 Adrian Saurin lab N/A
RFWD3 hypomorphic HeLa cells this paper N/A
ERCC1 knockout HeLa cells this paper N/A
Oligonucleotides
Scramble siRNA: UCCACAACAUAAUCCUAAUUU Invitrogen N/A
FANCD2 siRNA #1: CAGAGUUUGCUUCACUCUCUAUU Invitrogen N/A
FANCD2 siRNA #2: CGGCUUCUCGGAAGUAAUUUAUU Invitrogen N/A
RPA32 siRNA: CCUAGUUUCACAAUCUGUU Invitrogen N/A
RFWD3 gRNA cloning forward primer: GGAAAGGACGA
AACACCGAAGTTACATGTATCGATGGGTTTTAGAGCTA
GAAAT
Invitrogen N/A
RFWD3 gRNA cloning reverse primer: ATTTCTAGCTCTA
AAACCCATCGATACATGTAACTTCGGTGTTTCGTCCT
TTCC
Invitrogen N/A
RFWD3 sequencing forward primer: TGGTACCTGGGG
AAGTTGTC
Invitrogen N/A
(Continued on next page)
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CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, John
Rouse (j.rouse@dundee.ac.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines and tissue culture
All cell lines used in this study were derived fromU2OS FRT Flp-In TRex or HeLa FRT FLAG-Cas9 cells. These cell lines were grown in
Dulbecco’s Modified Eagle Medium (DMEM) plus 10% fetal bovine serum (FBS), 1% penicillin/streptomycin and 1% L-glutamine.
Additionally, 100 mg/ml hygromycin and 15 mg/ml blasticidin were added for the culture of Flp-In TRex stable cell lines. All cell lines
were grown at 37C and 5% CO2.
METHOD DETAILS
Genome editing
Genome editing was carried out as described previously (Munoz et al., 2014). Briefly, Cas9 expression in HeLa FRT cells stably
expressing FLAG-tagged Cas9 was induced by addition of tetracycline (1 mg/ml) and after a further 16h cells were transfected
with a plasmid expressing a guide (g)RNA targeting either exon 4 of RFWD3 (GAAGTTACATGTATCGATGGAGG) or exon 2 of
ERCC1 (GATACCCCTCGACGAGGATGAGG). Cells were then selected with puromycin (3 mg/ml) for 24h, before single cell cloning.
Individual clones were grown up, and screened for knockout by western blot and PCR followed by restriction enzyme digest with ClaI
(RFWD3) or Taq1 (ERCC1).
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
RFWD3 sequencing reverse primer: CTTAAACACGG
GAGGCAGAG
Invitrogen N/A
ERCC1 cloning forward primer: GGAAAGGACGAAA
CACCGATACCCCTCGACGAGGATGGTTTTAGAGC
TAGAAAT
Invitrogen N/A
ERCC1 cloning reverse primer: ATTTCTAGCTCTAA
AACCATCCTCGTCGAGGGGTATCGGTGTTTCGTC
CTTTCC
Invitrogen N/A
ERCC1 sequencing forward primer: GGAGCTCTCG
GAGTTTTGTG
Invitrogen N/A
ERCC1 sequencing reverse primer: AGTGTCTGGCC
TCTGCCTTA
Invitrogen N/A
Recombinant DNA
pcDNA5 FRT/TO GFP-RFWD3 this paper DU49512
pcDNA5 FRT/TO RFWD3-GFP this paper DU49591
pcDNA5 FRT/TO GFP-RFWD3 C315A this paper DU49582
pcDNA5 FRT/TO GFP-RFWD3 I639K this paper DU49590
pcDNA5 FRT/TO GFP-RFWD3 C315A I639K this paper DU50397
pcDNA5 FRT/TO GFP-RFWD3 C315A W543A this paper DU53212
pcDNA5 FRT/TO GFP-RFWD3 C315A Q499A this paper DU53211
pcDNA5 FRT/TO GFP-RFWD3 C315A L518A this paper DU53189
pcDNA5 FRT/TO 6xHis-3xFLAG-RPA32 this paper DU53226
pcDNA5 FRT/TO 6xHis-3xFLAG-RPA32 F248A this paper DU53308
pcDNA5 FRT/TO 6xHis-3xFLAG-RPA32 E252A this paper DU53309
pcDNA5 FRT/TO 6xHis-3xFLAG-RPA32 G253A this paper DU53310
pcDNA5 FRT/TO 6xHis-3xFLAG-RPA32 H254A this paper DU53315
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RT-PCR and sequencing
RT-PCR was carried out as previously described (Lachaud et al., 2016a). Briefly, total mRNA was extracted from cells using a
QIAGEN RNeasy kit and RT-PCR carried out using a Clontech RT-PCR kit. Oligos were designed to amplify sequences between
exons 3 (TGAGAGCACCATTGGATGC) and 5 (ACAGCGTAATGCTGAGAGCC) of the RFWD3 mRNA. Sequencing was carried out
by the DNA sequencing team at the University of Dundee.
Cell lysis and immunoprecipitation
Cells were lysed in ice cold buffer: 50mM Tris-HCl pH 7.5 plus 150mMNaCl, 270mM sucrose, 1% Triton X-100 and 0.5% NP40 with
protease inhibitor cocktail (Roche), 10mM iodoacetamide, 10ng/ml microcystin-LR and 0.5U/ml benzonase. Lysates were incubated
on ice for 30 min. All immunoprecipitations were carried out at 4C for 2h, except for FLAG-RPA32 immunoprecipitations that were
carried out for 16 hr.
MTS assay
Cells were diluted to 2x104 cells/ml and 100 mL of cell suspension was seeded per well in a 96 well plate. After 24h, cells were treated
withMMC (100 ng/ml) and incubated for a further 48h. Finally, 20 mLMTS reagent was added per well, and absorbance at 490nmwas
read. For each cell line, the viability of untreated cells was taken to represent a cell viability of 100%.
Clonogenic survival assay
For HeLa cells, 750 cells were seeded per 10cm dish and allowed to adhere for 4-6h. For U2OS, 1000 cells were seeded per 10cm
dish and allowed to adhere for the same time. Cells were then treated with the relevant genotoxin for 16h (for MMC, cisplatin and HU),
at which point cells were washed free of drugs. In the case of IR, no media change was required. Likewise, no media change was
carried out for olaparib as chronic treatment is required. Cells were then incubated for 1 – 2 weeks until visible colonies had formed.
Colonies were washed with 1x PBS followed by methanol, then stained with crystal violet, washed with water and counted.
Cell cycle analysis
Cells were seeded at low confluency in 10cm dishes and allowed to adhere before being treated with 2ng/ml MMC for 24 hr (HeLa) or
48 hr (U2OS). Cells were then fixed in 70% ethanol and stained with propidium iodide. Cell cycle distribution was analyzed using a
FACS Canto machine.
Chromosome abnormalities
Chromosome abnormalities weremeasured as previously described (Castor et al., 2013). Briefly, cells were seeded at low confluency
in 10cm dishes, and allowed to adhere before being treated with 2ng/ml MMC. After 24 hr, cells were treated with 0.1 mg/ml colcemid
(Sigma) for 2 hr. Samples were then harvested, washed with PBS, and incubated with 75mM KCl for 20 min at 37C. Samples were
fixed in methanol/acetic acid (3:1) and dropped on slides to generate metaphase spreads. Chromosomes were stained with Giemsa
(VWR) and abnormalities were counted using a 100x objective on a Zeiss 710 confocal microscope.
Psoralen/UV laser micro-irradiation
Localized micro-irradiation was induced as previously described (Perez-Oliva et al., 2015). Briefly, cells were seeded in glass-
bottomed dishes and treated with 1 mg/ml tetracycline as required to induceGFP-RFWD3 expression. After 24h, cells were incubated
with psoralen (50 mM) in Leibowitz medium for 2h. A Zeiss PALM microdissection microscope equipped with a 360nm UV laser was
then used to damage 100 nuclei per dish.
Immunofluorescence and confocal microscopy
Cells were pre-extracted with 0.2% Triton X-100 for 2-5 min, then fixed for 10 min in 3% paraformaldehyde. Permeablization was
carried out for 20 min with 0.2% Triton X-100, followed by blocking for 1h at room temperature in antibody dilution buffer (PBS
plus 5% donkey serum, 0.1% fish skin gelatin, 0.1% Triton X-100, 0.05% Tween and 0.05% sodium azide). Samples were then incu-
bated in primary antibody overnight at 4C, washed with 0.2% PBS-Tween, and incubated with secondary antibody for one hour at
room temperature in the dark. Finally, samples were washed with 0.2% PBS-Tween, DAPI stained and imaged using a Zeiss 710
confocal microscope.
High resolution microscopy
Samples were prepared as per the standard immunofluorescence protocol (see above), then mounted with coverslips using Prolong
Diamond anti-fademountant (Thermo Fisher). High-resolution images of RPA andRAD51 foci in single nuclei were then obtainedwith
Hyvolution software on a Leica SP8 confocal microscope, using a 63x oil immersion lens and a pinhole of 0.5 AU.
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In vitro ubiquitylation assay
1 mg RFWD3 (wild-type or C315A) was incubated in reaction buffer (250mM HEPES, 10mM MgCl2, 0.5mM TCEP) with 100ng E1,
200ng UBC13-UEV1A and 2 mg ubiquitin at 30C. Reactions were started with the addition of 0.5mM ATP. Reactions were stopped
after 30 min by the addition of loading buffer (Nupage) supplemented with reducing agent.
Proximity ligation assay (PLA)
Cells were pre-extracted, fixed, stained and blocked as per the standard immunofluorescence procedure (see above). Primary
antibodies conjugated to either Duolink Plus or Duolink Minus probes were generated using a Sigma Duolink probemaker kit as
per manufacturer’s instructions. Samples were incubated with conjugated primary antibodies overnight at 4C, then washed with
1x wash buffer A (10mM Tris-HCl pH7.5, 150mM NaCl, 0.05% Tween), and incubated with ligase diluted 1:40 in 1x ligation buffer
(Sigma Duolink detection kit green) for 30 min at 37C. Next, samples were washed again with 1x wash buffer A then incubated
for 100 min at 37C with polymerase diluted 1:80 in 1x amplification buffer (Sigma Duolink detection kit green). Finally, samples
were washed with 1x wash buffer B (200mM Tris-HCl pH7.5, 100mM NaCl) followed by 0.01x wash buffer B, then DAPI stained
and imaged using a Zeiss 710 confocal microscope.
QUANTIFICATION AND STATISTICAL ANALYSIS
Details of statistical analysis can be found in the legends to the relevant figures. In each case, the sample size (n) refers to the number
of independent experiments, and data are represented as mean ± standard error of the mean (SEM).
DATA AND SOFTWARE AVAILABILITY
The raw data files for imaging data presented in this manuscript have been deposited toMendeley Data and are available at http://dx.
doi.org/10.17632/brzwywcrbj.1.
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